Stage III N2 non-small cell lung cancer treatment: decision-making among surgeons and radiation oncologists-Reference-Cited by-同舟云学术

Stage III N2 non-small cell lung cancer treatment: decision-making among surgeons and radiation oncologists

Published:2021-04 Issue:4 Volume:10 Page:1960-1968
ISSN:2218-6751
Container-title:Translational Lung Cancer Research
language:
Short-container-title:Transl Lung Cancer Res

Author:

Glatzer Markus,Leskow Pawel,Caparrotti Francesca,Elicin Olgun,Furrer Markus,Gambazzi Franco,Dutly André,Gelpke Hans,Guckenberger Matthias,Heuberger Jürg,Inderbitzi Rolf,Cafarotti Stefano,Karenovics Wolfram,Kestenholz Peter,Kocher Gregor Jan,Kraxner Peter,Krueger Thorsten,Martucci Francesco,Oehler Christoph,Ozsahin Mahmut,Papachristofilou Alexandros,Wagnetz Dirk,Zaugg Kathrin,Zwahlen Daniel,Opitz Isabelle,Putora Paul Martin

Publisher

AME Publishing Company

Subject

Oncology

Link

https://tlcr.amegroups.com/article/download/51602/pdf

Cited by 18 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A prospective analysis of the management practices for patients with Stage-III-N2Non-Small-Cell lung cancer (OBSERVE IIIA–B GFPC 04-2020Study);Lung Cancer;2024-08

2. EBUS-TBNA in mediastinal staging of non-small cell lung cancer: comparison with pathological staging;Jornal Brasileiro de Pneumologia;2024-07-23

3. Prognostic biomarker tumor-infiltrating lymphocytes failed to serve as a predictive biomarker for postoperative radiotherapy in completely resected pN2 non-small cell lung cancer: a retrospective analysis;Respiratory Research;2024-06-17

4. Chemoradiotherapy versus surgery after neoadjuvant chemoimmunotherapy in patients with stage III NSCLC: a real-world multicenter retrospective study;Cancer Immunology, Immunotherapy;2024-05-07

5. Boosting immune responses in lung tumor immune microenvironment: A comprehensive review of strategies and adjuvants;International Reviews of Immunology;2024-03-25